Pfizer Inc. (PFE)

36.34
0.16 0.44
NYSE : Health Technology
Prev Close 36.50
Open 36.63
Day Low/High 36.32 / 36.75
52 Wk Low/High 33.97 / 46.47
Volume 13.71M
Avg Volume 24.08M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 200.78B
EPS 1.90
P/E Ratio 16.35
Div & Yield 1.44 (3.93%)
Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

NEW ORLEANS, June 7, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

Jim Cramer takes a look at PayPal, Tesla, Pfizer, Americold Realty Trust, Continental Resources, United Natural Foods, Cintas, Splunk and more.

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #205 spot out of 500.

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary...

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Inc. (NYSE:PFE) will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4,...

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and...

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.

Sweet Taste of Fear

Sentiment's shifting, we're getting oversold and it looks like fear and panic are creeping in -- that's the way it should be.

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the...

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA ® (lorlatinib, available in the U.

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

The FDA approves Pfizer's treatment for a rare form of heart disease.

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

S&P Closes at Record High as Alphabet Weighs Down Nasdaq

Stocks ended mixed as the S&P 500 set a record close and the Nasdaq slumped on a revenue miss from Alphabet.

Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer posted stronger-than-expected first quarter earnings Tuesday, and boosted the mid-point of its full-year profit forecast thanks to anticipated gains in consumer healthcare.

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Global stocks slipped lower for a second consecutive session Tuesday, pulling U.S. equity futures into the red, as investors reacted to renewed weakness in China's manufacturing sector and braced for the impact of softer-than-expected revenue gains from online ad giant Alphabet Inc.

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2).

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Global stocks were mixed Monday as investors extended bets that surging economic growth, stronger-than-expected corporate earnings and a potentially dovish Federal Reserve will continue to push U.S. stocks to fresh record highs.

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP)...

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Pfizer Hosts Annual Meeting Of Shareholders

Pfizer Hosts Annual Meeting Of Shareholders

The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company's common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019.

TheStreet Quant Rating: B (Buy)